Shares of VivoSim Labs (NASDAQ: VIVS) soared 60% this morning after the company announced a seven-figure agreement with one of the world's 10 largest pharmaceutical companies. 

‍

The San Diego-based biotech services company didn't disclose the customer's name or the exact value of the agreement. However, it confirmed that the deal is worth at least $1 million and involves testing experimental drugs for potential liver and intestinal damage. As a result, VivoSim now expects fiscal 2027 revenue growth to exceed its previous forecast of more than 500%.

‍

Work under the agreement has already begun, with revenue expected to be recognized during the company's fiscal third and fourth quarters, ending December 31, 2026, and March 31, 2027.

‍

Testing new drugs without relying on animals

‍

VivoSim develops three-dimensional models of human liver and intestinal tissue that pharmaceutical companies can use to evaluate experimental drugs before testing them in people.

‍

Traditionally, drug developers have relied heavily on animal testing to determine whether new medications might cause serious side effects.

‍

Unfortunately, drugs that appear safe in animals don't always produce the same results in humans. Some fail during clinical trials because they damage the liver or cause other complications that weren't detected earlier.

‍

VivoSim's NAMkind technology uses actual human cells to help identify those problems before companies spend millions of dollars advancing a drug into clinical trials.

‍

According to VivoSim, its liver model correctly predicted drug-induced liver injury with 91% accuracy across a dataset of 92 experimental compounds.

‍

The company also reported 90% sensitivity and 95% specificity, meaning the technology demonstrated a strong ability to identify potentially harmful drugs while distinguishing them from safer compounds.

‍

Those results are encouraging, although additional testing across larger and more diverse groups of drugs will help establish how reliably the technology performs.

‍

A major pharmaceutical customer could mean recurring business

‍

The new agreement follows an evaluation period during which the pharmaceutical customer tested VivoSim's technology against drugs with already-known clinical outcomes. The customer has now moved beyond that initial evaluation and begun paying VivoSim to test drugs in its development pipeline.

‍

VivoSim expects its technology could eventually become part of the customer's regular drug-testing process. And that could potentially generate recurring revenue rather than occasional testing contracts.

‍

VivoSim has also expanded its services to include testing AI-designed drugs through a recently announced collaboration with Chemveda Life Sciences.

‍

Meanwhile, the FDA has been encouraging greater use of scientifically validated non-animal testing methods in drug development.

‍

For VivoSim, the combination of growing pharmaceutical demand, encouraging testing results, and a seven-figure commercial agreement could support substantial revenue growth over the next several years.

‍

Of course, the company still needs to demonstrate that it can turn these early commercial agreements into a sustainable, profitable business. But today’s announcement provides evidence that major pharmaceutical companies are willing to pay for its technology, rather than simply evaluate it in preliminary studies.

‍